SAN DIEGO, March 13, 2019 /PRNewswire/ -- Epic Sciences, Inc. (Epic) today announced the publication of results from a multicenter prospective trial validating the biomarker AR-V7 (androgen receptor ...
High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers In all, 142 (95%) of 150 questionnaires were completed by 38 ...
Long-term follow-up from STAMP, a phase II trial, evaluating sipuleucel-T and concurrent (CON) vs sequential (SEQ) abiraterone acetate + prednisone in metastatic castration-resistant prostate cancer ...
Genomic Health, Inc.GHDX recently inked an exclusive deal with private diagnostic provider Epic Sciences to market and sell the latter's liquid biopsy test - AR-V7. Notably, the test will be available ...
This study used a blood test to look for a biomarker called AR-V7. This was to help doctors work out the best treatment for prostate cancer that had spread to other parts of the body. This is ...
SAN DIEGO (KGTV) -- As an active 45-year-old man who loves to surf and take adventures with his daughter, Bryce Olson was the last person his friends expected to get cancer. In 2014, a call while at ...
Finding needles in a haystack is the life-and-death job of San Diego’s Epic Sciences. The needles are extremely rare cancer cells that hide among the millions of normal cells in the blood of cancer ...
Genomic Health, Inc. GHDX recently inked an exclusive deal with private diagnostic provider Epic Sciences to market and sell the latter’s liquid biopsy test – AR-V7. Notably, the test will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results